Answers are grounded in this paper and cite their sources.
Negative trial reveals the need for precision strategies in addressing immunotherapy resistance in NSCLC, highlighting implications for treatment approaches.
Immune checkpoint inhibitors combined with platinum-based chemotherapy have become the first-line backbone for advanced, driver-negative non-small cell lung cancer (NSCLC), delivering meaningful survival gains; yet for most, disease control ultimately erodes, making immunotherapy resistance one of the most pressing unmet needs.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: